Loading
Pheast Therapeutics makes an antibody that removes a 'don't eat me' signal, CD24, that cancer cells use to hide from macrophages, immune cells that swallow and destroy them. It is in a first trial in advanced solid tumours.
Pheast Therapeutics, a private company in Redwood City, California, was co-founded from the Stanford laboratory of Irv Weissman, with Ravi Majeti among its cofounders and Roy Maute as cofounder and chief executive, building on the 2019 Nature report that CD24 acts as a macrophage 'don't eat me' signal in ovarian and breast cancer. Its lead PHST001 is an anti-CD24 antibody in a phase 1 trial (NCT06840886) of up to 80 patients with advanced solid tumours, alone and with chemotherapy or mirvetuximab soravtansine in cohorts including ovarian, endometrial and biliary cancer; the first patient was treated in April 2025 and initial phase 1a data were reported at AACR 2026. It is also developing PHST677, a bispecific ADC targeting CDH1 and Nectin-4. Its first registered cancer trial, NCT06840886, was posted on ClinicalTrials.gov in February 2025.
Shares CD24, Monoclonal antibodies.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/